25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

PolyPeptide Group AG
Buy, Hold or Sell?

Let's analyze Polypeptide together

I guess you are interested in PolyPeptide Group AG. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of PolyPeptide Group AG. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about PolyPeptide Group AG

I send you an email if I find something interesting about PolyPeptide Group AG.

1. Quick Overview

1.1. Quick analysis of Polypeptide (30 sec.)










1.2. What can you expect buying and holding a share of Polypeptide? (30 sec.)

How much money do you get?

How much money do you get?
CHF0.00
When do you have the money?
1 year
How often do you get paid?
66.7%

What is your share worth?

Current worth
CHF10.89
Expected worth in 1 year
CHF6.30
How sure are you?
83.3%

+ What do you gain per year?

Total Gains per Share
CHF-4.59
Return On Investment
-16.0%

For what price can you sell your share?

Current Price per Share
CHF28.80
Expected price per share
CHF26.02 - CHF32.15
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Polypeptide (5 min.)




Live pricePrice per Share (EOD)
CHF28.80
Intrinsic Value Per Share
CHF-18.23 - CHF-9.75
Total Value Per Share
CHF-7.34 - CHF1.15

2.2. Growth of Polypeptide (5 min.)




Is Polypeptide growing?

Current yearPrevious yearGrowGrow %
How rich?$413.2m$457.1m-$43.8m-10.6%

How much money is Polypeptide making?

Current yearPrevious yearGrowGrow %
Making money-$55.7m$8.4m-$64.1m-115.1%
Net Profit Margin-16.1%2.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Polypeptide (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Polypeptide?

Welcome investor! Polypeptide's management wants to use your money to grow the business. In return you get a share of Polypeptide.

First you should know what it really means to hold a share of Polypeptide. And how you can make/lose money.

Speculation

The Price per Share of Polypeptide is CHF28.80. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Polypeptide.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Polypeptide, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is CHF10.89. Based on the TTM, the Book Value Change Per Share is CHF-1.15 per quarter. Based on the YOY, the Book Value Change Per Share is CHF0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is CHF0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Polypeptide.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 CHF% of Price per ShareCHF% of Price per ShareCHF% of Price per ShareCHF% of Price per ShareCHF% of Price per Share
Usd Eps-1.69-5.9%-1.69-5.9%0.260.9%0.401.4%0.461.6%
Usd Book Value Change Per Share-1.32-4.6%-1.32-4.6%0.010.0%1.545.3%2.097.3%
Usd Dividend Per Share0.000.0%0.000.0%0.321.1%0.291.0%0.240.8%
Usd Total Gains Per Share-1.32-4.6%-1.32-4.6%0.331.1%1.826.3%2.338.1%
Usd Price Per Share20.15-20.15-29.12-41.37-34.48-
Price to Earnings Ratio-11.92--11.92-114.16-40.74-33.95-
Price-to-Total Gains Ratio-15.26--15.26-89.43-30.91-30.91-
Price to Book Ratio1.61-1.61-2.10-3.02-2.52-
Price-to-Total Gains Ratio-15.26--15.26-89.43-30.91-30.91-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share33.12576
Number of shares30
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.29
Usd Book Value Change Per Share-1.321.54
Usd Total Gains Per Share-1.321.82
Gains per Quarter (30 shares)-39.6354.73
Gains per Year (30 shares)-158.52218.93
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-159-16935184209
20-317-32869368428
30-476-487104553647
40-634-646139737866
50-793-8051749211085
60-951-96420811051304
70-1110-112324312901523
80-1268-128227814741742
90-1427-144131216581961
100-1585-160034718422180

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%2.01.00.066.7%4.01.00.080.0%5.01.00.083.3%5.01.00.083.3%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%4.01.00.080.0%5.01.00.083.3%5.01.00.083.3%
Dividend per Share0.00.01.00.0%2.00.01.066.7%4.00.01.080.0%4.00.02.066.7%4.00.02.066.7%
Total Gains per Share0.01.00.00.0%2.01.00.066.7%4.01.00.080.0%5.01.00.083.3%5.01.00.083.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of PolyPeptide Group AG compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.148-1.1480%0.007-16614%1.335-186%1.816-163%
Book Value Per Share--10.89310.8930%12.042-10%8.863+23%8.089+35%
Current Ratio--1.8511.8510%2.619-29%2.392-23%2.361-22%
Debt To Asset Ratio--0.4470.4470%0.268+67%0.409+9%0.421+6%
Debt To Equity Ratio--0.8080.8080%0.365+121%0.749+8%0.778+4%
Dividend Per Share----0%0.276-100%0.251-100%0.210-100%
Eps---1.470-1.4700%0.222-763%0.347-524%0.402-465%
Free Cash Flow Per Share---0.579-0.5790%-2.093+262%-0.395-32%-0.307-47%
Free Cash Flow To Equity Per Share--1.8371.8370%-2.861+256%0.439+318%0.372+394%
Gross Profit Margin--1.0311.0310%0.368+180%0.831+24%0.850+21%
Intrinsic Value_10Y_max---9.748--------
Intrinsic Value_10Y_min---18.231--------
Intrinsic Value_1Y_max---0.522--------
Intrinsic Value_1Y_min---1.285--------
Intrinsic Value_3Y_max---1.914--------
Intrinsic Value_3Y_min---4.352--------
Intrinsic Value_5Y_max---3.725--------
Intrinsic Value_5Y_min---7.936--------
Market Cap949927680.000+39%577872672.000577872672.0000%835661254.680-31%1186457425.336-51%988714521.113-42%
Net Profit Margin---0.161-0.1610%0.028-681%0.060-366%0.072-322%
Operating Margin---0.164-0.1640%0.025-760%0.086-290%0.098-268%
Operating Ratio--1.1141.1140%0.966+15%0.902+23%0.892+25%
Pb Ratio2.644+39%1.6081.6080%2.103-24%3.019-47%2.516-36%
Pe Ratio-19.593-64%-11.919-11.9190%114.155-110%40.738-129%33.948-135%
Price Per Share28.800+39%17.52017.5200%25.320-31%35.968-51%29.973-42%
Price To Free Cash Flow Ratio-49.777-64%-30.281-30.2810%-12.095-60%-55.581+84%-46.318+53%
Price To Total Gains Ratio-25.077-64%-15.255-15.2550%89.429-117%30.907-149%30.907-149%
Quick Ratio--1.1151.1150%0.902+24%1.127-1%1.076+4%
Return On Assets---0.075-0.0750%0.013-653%0.037-301%0.045-266%
Return On Equity---0.135-0.1350%0.018-833%0.069-296%0.084-260%
Total Gains Per Share---1.148-1.1480%0.283-506%1.586-172%2.025-157%
Usd Book Value--413272107.788413272107.7880%457124644.490-10%336309236.418+23%306939029.231+35%
Usd Book Value Change Per Share---1.321-1.3210%0.008-16614%1.535-186%2.088-163%
Usd Book Value Per Share--12.53012.5300%13.851-10%10.195+23%9.304+35%
Usd Dividend Per Share----0%0.318-100%0.289-100%0.241-100%
Usd Eps---1.691-1.6910%0.255-763%0.399-524%0.463-465%
Usd Free Cash Flow---21950117.748-21950117.7480%-79466190.804+262%-14993031.830-32%-11654947.366-47%
Usd Free Cash Flow Per Share---0.665-0.6650%-2.408+262%-0.454-32%-0.353-47%
Usd Free Cash Flow To Equity Per Share--2.1132.1130%-3.290+256%0.505+318%0.428+394%
Usd Market Cap1092606817.536+39%664669147.334664669147.3340%961177575.133-31%1364663330.621-51%1137219442.185-42%
Usd Price Per Share33.126+39%20.15220.1520%29.123-31%41.370-51%34.475-42%
Usd Profit---55764226.440-55764226.4400%8419921.205-762%13151207.944-524%15263072.048-465%
Usd Revenue--347303591.622347303591.6220%304597994.103+14%284108109.890+22%269201694.733+29%
Usd Total Gains Per Share---1.321-1.3210%0.326-506%1.824-172%2.329-157%
 EOD+5 -3MRQTTM+0 -0YOY+12 -245Y+10 -2610Y+11 -25

3.3 Fundamental Score

Let's check the fundamental score of PolyPeptide Group AG based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-19.593
Price to Book Ratio (EOD)Between0-12.644
Net Profit Margin (MRQ)Greater than0-0.161
Operating Margin (MRQ)Greater than0-0.164
Quick Ratio (MRQ)Greater than11.115
Current Ratio (MRQ)Greater than11.851
Debt to Asset Ratio (MRQ)Less than10.447
Debt to Equity Ratio (MRQ)Less than10.808
Return on Equity (MRQ)Greater than0.15-0.135
Return on Assets (MRQ)Greater than0.05-0.075
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of PolyPeptide Group AG based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.641
Ma 20Greater thanMa 5028.573
Ma 50Greater thanMa 10030.713
Ma 100Greater thanMa 20030.524
OpenGreater thanClose28.450
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About PolyPeptide Group AG

PolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of peptide-based therapies for metabolic disorders, including the GLP-1 receptor agonist drugs for the treatment of type 2 diabetes, obesity, and other co-morbidities, as well as oncology, hormonal disorders, neurology, ophthalmology, cardiovascular, and gastrointestinal applications. It also provides peptides for cosmetics; and individualized peptide therapeutics. The company was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.

Fundamental data was last updated by Penke on 2024-10-16 14:26:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Polypeptide earns for each CHF1 of revenue.

  • Above 10% is considered healthy but always compare Polypeptide to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -16.1% means that CHF-0.16 for each CHF1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of PolyPeptide Group AG:

  • The MRQ is -16.1%. The company is making a huge loss. -2
  • The TTM is -16.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-16.1%TTM-16.1%0.0%
TTM-16.1%YOY2.8%-18.8%
TTM-16.1%5Y6.0%-22.1%
5Y6.0%10Y7.2%-1.2%
4.3.1.2. Return on Assets

Shows how efficient Polypeptide is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Polypeptide to the Drug Manufacturers - Specialty & Generic industry mean.
  • -7.5% Return on Assets means that Polypeptide generated CHF-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of PolyPeptide Group AG:

  • The MRQ is -7.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -7.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.5%TTM-7.5%0.0%
TTM-7.5%YOY1.3%-8.8%
TTM-7.5%5Y3.7%-11.2%
5Y3.7%10Y4.5%-0.8%
4.3.1.3. Return on Equity

Shows how efficient Polypeptide is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Polypeptide to the Drug Manufacturers - Specialty & Generic industry mean.
  • -13.5% Return on Equity means Polypeptide generated CHF-0.13 for each CHF1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of PolyPeptide Group AG:

  • The MRQ is -13.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -13.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.5%TTM-13.5%0.0%
TTM-13.5%YOY1.8%-15.3%
TTM-13.5%5Y6.9%-20.4%
5Y6.9%10Y8.4%-1.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of PolyPeptide Group AG.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Polypeptide is operating .

  • Measures how much profit Polypeptide makes for each CHF1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Polypeptide to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of -16.4% means the company generated CHF-0.16  for each CHF1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of PolyPeptide Group AG:

  • The MRQ is -16.4%. The company is operating very inefficient. -2
  • The TTM is -16.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-16.4%TTM-16.4%0.0%
TTM-16.4%YOY2.5%-18.9%
TTM-16.4%5Y8.6%-25.0%
5Y8.6%10Y9.8%-1.2%
4.3.2.2. Operating Ratio

Measures how efficient Polypeptide is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.11 means that the operating costs are CHF1.11 for each CHF1 in net sales.

Let's take a look of the Operating Ratio trends of PolyPeptide Group AG:

  • The MRQ is 1.114. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.114. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.114TTM1.1140.000
TTM1.114YOY0.966+0.148
TTM1.1145Y0.902+0.212
5Y0.90210Y0.892+0.009
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of PolyPeptide Group AG.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Polypeptide is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.85 means the company has CHF1.85 in assets for each CHF1 in short-term debts.

Let's take a look of the Current Ratio trends of PolyPeptide Group AG:

  • The MRQ is 1.851. The company is able to pay all its short-term debts. +1
  • The TTM is 1.851. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.851TTM1.8510.000
TTM1.851YOY2.619-0.768
TTM1.8515Y2.392-0.541
5Y2.39210Y2.361+0.030
4.4.3.2. Quick Ratio

Measures if Polypeptide is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Polypeptide to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.12 means the company can pay off CHF1.12 for each CHF1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of PolyPeptide Group AG:

  • The MRQ is 1.115. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.115. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.115TTM1.1150.000
TTM1.115YOY0.902+0.213
TTM1.1155Y1.127-0.012
5Y1.12710Y1.076+0.051
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of PolyPeptide Group AG.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Polypeptide assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Polypeptide to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.45 means that Polypeptide assets are financed with 44.7% credit (debt) and the remaining percentage (100% - 44.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of PolyPeptide Group AG:

  • The MRQ is 0.447. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.447. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.447TTM0.4470.000
TTM0.447YOY0.268+0.179
TTM0.4475Y0.409+0.038
5Y0.40910Y0.421-0.012
4.5.4.2. Debt to Equity Ratio

Measures if Polypeptide is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Polypeptide to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 80.8% means that company has CHF0.81 debt for each CHF1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of PolyPeptide Group AG:

  • The MRQ is 0.808. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.808. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.808TTM0.8080.000
TTM0.808YOY0.365+0.442
TTM0.8085Y0.749+0.059
5Y0.74910Y0.778-0.029
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every CHF1 in earnings Polypeptide generates.

  • Above 15 is considered overpriced but always compare Polypeptide to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -11.92 means the investor is paying CHF-11.92 for every CHF1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of PolyPeptide Group AG:

  • The EOD is -19.593. Based on the earnings, the company is expensive. -2
  • The MRQ is -11.919. Based on the earnings, the company is expensive. -2
  • The TTM is -11.919. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-19.593MRQ-11.919-7.674
MRQ-11.919TTM-11.9190.000
TTM-11.919YOY114.155-126.074
TTM-11.9195Y40.738-52.657
5Y40.73810Y33.948+6.790
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of PolyPeptide Group AG:

  • The EOD is -49.777. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -30.281. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -30.281. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-49.777MRQ-30.281-19.496
MRQ-30.281TTM-30.2810.000
TTM-30.281YOY-12.095-18.185
TTM-30.2815Y-55.581+25.300
5Y-55.58110Y-46.318-9.264
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Polypeptide is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 1.61 means the investor is paying CHF1.61 for each CHF1 in book value.

Let's take a look of the Price to Book Ratio trends of PolyPeptide Group AG:

  • The EOD is 2.644. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.608. Based on the equity, the company is underpriced. +1
  • The TTM is 1.608. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.644MRQ1.608+1.035
MRQ1.608TTM1.6080.000
TTM1.608YOY2.103-0.494
TTM1.6085Y3.019-1.411
5Y3.01910Y2.516+0.503
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Income before Tax  28,4957,02435,51820,88956,407-49,2757,132-62,026-54,894
Net Income  24,2575,27629,53315,00744,541-37,2207,320-55,803-48,482
EBIT  31,6636,87738,54120,62359,164-52,5756,588-56,182-49,594
EBITDA  46,5628,51555,07723,58078,657-47,50531,152-52,030-20,877
Operating Income  31,62010,14341,76321,76263,525-51,71911,807-46,178-34,371
Income Tax Expense  4,2371,7475,9855,88111,866-11,678189-6,600-6,412
Net Income from Continuing Operations  24,2575,27629,53315,00744,541-37,2207,320-55,803-48,482



6.2. Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets689,088
Total Liabilities307,863
Total Stockholder Equity381,225
 As reported
Total Liabilities 307,863
Total Stockholder Equity+ 381,225
Total Assets = 689,088

Assets

Total Assets689,088
Total Current Assets326,602
Long-term Assets362,486
Total Current Assets
Cash And Cash Equivalents 95,706
Net Receivables 101,073
Inventory 128,507
Other Current Assets 1,316
Total Current Assets  (as reported)326,602
Total Current Assets  (calculated)326,602
+/-0
Long-term Assets
Property Plant Equipment 324,105
Intangible Assets 16,454
Long-term Assets Other 5,237
Long-term Assets  (as reported)362,486
Long-term Assets  (calculated)345,796
+/- 16,690

Liabilities & Shareholders' Equity

Total Current Liabilities176,450
Long-term Liabilities131,413
Total Stockholder Equity381,225
Total Current Liabilities
Short-term Debt 45,706
Short Long Term Debt 41,253
Accounts payable 60,906
Other Current Liabilities 1,391
Total Current Liabilities  (as reported)176,450
Total Current Liabilities  (calculated)149,256
+/- 27,194
Long-term Liabilities
Long term Debt 49,087
Capital Lease Obligations 23,322
Long-term Liabilities  (as reported)131,413
Long-term Liabilities  (calculated)72,409
+/- 59,004
Total Stockholder Equity
Common Stock302
Retained Earnings 165,139
Accumulated Other Comprehensive Income 23,049
Other Stockholders Equity 192,735
Total Stockholder Equity (as reported)381,225
Total Stockholder Equity (calculated)381,225
+/-0
Other
Capital Stock302
Cash and Short Term Investments 95,706
Common Stock Shares Outstanding 32,968
Current Deferred Revenue68,447
Liabilities and Stockholders Equity 689,088
Net Debt 17,956
Net Invested Capital 471,565
Net Working Capital 150,152
Property Plant and Equipment Gross 498,855
Short Long Term Debt Total 113,662



6.3. Balance Sheets Structured

Currency in EUR. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
> Total Assets 
283,826
305,142
375,975
595,038
575,782
689,088
689,088575,782595,038375,975305,142283,826
   > Total Current Assets 
141,250
142,669
179,862
331,606
251,570
326,602
326,602251,570331,606179,862142,669141,250
       Cash And Cash Equivalents 
10,037
17,508
17,208
136,303
37,528
95,706
95,70637,528136,30317,20817,50810,037
       Net Receivables 
42,369
35,449
55,538
67,789
49,146
101,073
101,07349,14667,78955,53835,44942,369
       Inventory 
72,334
73,490
94,269
113,001
145,073
128,507
128,507145,073113,00194,26973,49072,334
   > Long-term Assets 
142,576
162,473
182,565
253,177
315,926
362,486
362,486315,926253,177182,565162,473142,576
       Property Plant Equipment 
115,802
136,635
169,808
235,442
297,294
324,105
324,105297,294235,442169,808136,635115,802
       Intangible Assets 
10,910
12,312
12,556
14,268
15,865
16,454
16,45415,86514,26812,55612,31210,910
       Other Assets 
12,613
13,067
13,548
10,255
8,286
0
08,28610,25513,54813,06712,613
> Total Liabilities 
136,152
155,726
198,315
173,865
154,105
307,863
307,863154,105173,865198,315155,726136,152
   > Total Current Liabilities 
63,944
56,302
101,848
103,961
96,052
176,450
176,45096,052103,961101,84856,30263,944
       Short-term Debt 
18,264
1,491
1,979
3,058
3,566
45,706
45,7063,5663,0581,9791,49118,264
       Short Long Term Debt 
18,264
0
0
0
0
41,253
41,253000018,264
       Accounts payable 
14,731
18,460
28,359
28,481
45,933
60,906
60,90645,93328,48128,35918,46014,731
       Other Current Liabilities 
28,652
1,360
73,489
75,480
50,119
1,391
1,39150,11975,48073,4891,36028,652
   > Long-term Liabilities 
72,208
99,424
35,902
10,302
9,410
131,413
131,4139,41010,30235,90299,42472,208
       Long term Debt Total 
25,000
33,869
35,454
14,947
27,062
0
027,06214,94735,45433,86925,000
       Other Liabilities 
47,208
52,842
50,111
44,655
30,991
0
030,99144,65550,11152,84247,208
> Total Stockholder Equity
147,674
149,416
177,660
421,173
421,677
381,225
381,225421,677421,173177,660149,416147,674
   Common Stock
50,000
33,000
33,000
302
302
302
30230230233,00033,00050,000
   Retained Earnings 
98,176
116,770
147,936
196,027
214,146
165,139
165,139214,146196,027147,936116,77098,176
   Accumulated Other Comprehensive Income 
-2,442
-2,694
-5,616
13,231
17,709
23,049
23,04917,70913,231-5,616-2,694-2,442
   Capital Surplus 
1,940
2,340
2,340
212,800
203,129
0
0203,129212,8002,3402,3401,940
   Treasury Stock000000



6.4. Balance Sheets

Currency in EUR. All numbers in thousands.




6.5. Cash Flows

Currency in EUR. All numbers in thousands.




6.6. Income Statements

Currency in EUR. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in EUR. All numbers in thousands.

Gross Profit (+$)
totalRevenue320,372
Cost of Revenue-315,730
Gross Profit4,6424,642
 
Operating Income (+$)
Gross Profit4,642
Operating Expense-41,110
Operating Income-36,468-36,468
 
Operating Expense (+$)
Research Development1,465
Selling General Administrative17,181
Selling And Marketing Expenses1,579
Operating Expense41,11020,225
 
Net Interest Income (+$)
Interest Income54
Interest Expense-5,623
Other Finance Cost-1,711
Net Interest Income-7,280
 
Pretax Income (+$)
Operating Income-36,468
Net Interest Income-7,280
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-58,243-14,693
EBIT - interestExpense = -58,243
-58,243
-45,817
Interest Expense5,623
Earnings Before Interest and Taxes (EBIT)-52,620-52,620
Earnings Before Interest and Taxes (EBITDA)-22,151
 
After tax Income (+$)
Income Before Tax-58,243
Tax Provision--6,803
Net Income From Continuing Ops-51,440-51,440
Net Income-51,440
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses356,840
Total Other Income/Expenses Net-21,7757,280
 

Technical Analysis of Polypeptide
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Polypeptide. The general trend of Polypeptide is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Polypeptide's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of PolyPeptide Group AG.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 31.00 < 31.60 < 32.15.

The bearish price targets are: 26.70 > 26.20 > 26.02.

Tweet this
PolyPeptide Group AG Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of PolyPeptide Group AG. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

PolyPeptide Group AG Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of PolyPeptide Group AG. The current macd is -0.38942093.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Polypeptide price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Polypeptide. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Polypeptide price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
PolyPeptide Group AG Daily Moving Average Convergence/Divergence (MACD) ChartPolyPeptide Group AG Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of PolyPeptide Group AG. The current adx is 15.46.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Polypeptide shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
PolyPeptide Group AG Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of PolyPeptide Group AG. The current sar is 30.94.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
PolyPeptide Group AG Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of PolyPeptide Group AG. The current rsi is 45.64. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
PolyPeptide Group AG Daily Relative Strength Index (RSI) ChartPolyPeptide Group AG Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of PolyPeptide Group AG. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Polypeptide price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
PolyPeptide Group AG Daily Stochastic Oscillator ChartPolyPeptide Group AG Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of PolyPeptide Group AG. The current cci is -4.63540738.

PolyPeptide Group AG Daily Commodity Channel Index (CCI) ChartPolyPeptide Group AG Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of PolyPeptide Group AG. The current cmo is -4.83340029.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
PolyPeptide Group AG Daily Chande Momentum Oscillator (CMO) ChartPolyPeptide Group AG Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of PolyPeptide Group AG. The current willr is -55.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Polypeptide is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
PolyPeptide Group AG Daily Williams %R ChartPolyPeptide Group AG Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of PolyPeptide Group AG.

PolyPeptide Group AG Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of PolyPeptide Group AG. The current atr is 1.04339715.

PolyPeptide Group AG Daily Average True Range (ATR) ChartPolyPeptide Group AG Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of PolyPeptide Group AG. The current obv is 248,826.

PolyPeptide Group AG Daily On-Balance Volume (OBV) ChartPolyPeptide Group AG Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of PolyPeptide Group AG. The current mfi is 67.15.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
PolyPeptide Group AG Daily Money Flow Index (MFI) ChartPolyPeptide Group AG Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for PolyPeptide Group AG.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-06-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-17STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-06-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-19STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-06-21STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-06-25BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-06-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-28STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-07-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-07-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-07-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-07-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-07-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-07-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-08-13STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-14MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-26MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-27STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-09-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-10CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-17CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-23BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-09-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-26ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-09-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-01BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-02MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-04RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-10-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside

6.3. Candlestick Patterns

PolyPeptide Group AG Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of PolyPeptide Group AG based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.641
Ma 20Greater thanMa 5028.573
Ma 50Greater thanMa 10030.713
Ma 100Greater thanMa 20030.524
OpenGreater thanClose28.450
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Polypeptide with someone you think should read this too:
  • Are you bullish or bearish on Polypeptide? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Polypeptide? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about PolyPeptide Group AG

I send you an email if I find something interesting about PolyPeptide Group AG.


Comments

How you think about this?

Leave a comment

Stay informed about PolyPeptide Group AG.

Receive notifications about PolyPeptide Group AG in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.